BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23125424)

  • 1. C3 glomerulonephritis and CFHR5 nephropathy.
    Gale DP; Maxwell PH
    Nephrol Dial Transplant; 2013 Feb; 28(2):282-8. PubMed ID: 23125424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families.
    Deltas C; Gale D; Cook T; Voskarides K; Athanasiou Y; Pierides A
    Adv Exp Med Biol; 2013; 735():189-96. PubMed ID: 23402027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.
    Malik TH; Gitterman DP; Lavin DP; Lomax-Browne HJ; Hiemeyer EC; Moran LB; Boroviak K; Cook HT; Gilmore AC; Mandwie M; Ahmad A; Alexander IE; Logan GJ; Marchbank KJ; Bradley A; Pickering MC
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
    Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-existence of Alport syndrome and C3 glomerulonephritis in a proband with family history.
    Ding Y; Tang X; Du Y; Chen H; Yu D; Zhu B; Yuan B
    Eur J Med Res; 2021 Jul; 26(1):71. PubMed ID: 34238373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees.
    Athanasiou Y; Voskarides K; Gale DP; Damianou L; Patsias C; Zavros M; Maxwell PH; Cook HT; Demosthenous P; Hadjisavvas A; Kyriacou K; Zouvani I; Pierides A; Deltas C
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1436-46. PubMed ID: 21566112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.
    Gale DP; de Jorge EG; Cook HT; Martinez-Barricarte R; Hadjisavvas A; McLean AG; Pusey CD; Pierides A; Kyriacou K; Athanasiou Y; Voskarides K; Deltas C; Palmer A; Frémeaux-Bacchi V; de Cordoba SR; Maxwell PH; Pickering MC
    Lancet; 2010 Sep; 376(9743):794-801. PubMed ID: 20800271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy.
    Frangou E; Varnavidou-Nicolaidou A; Petousis P; Soloukides A; Theophanous E; Savva I; Michael N; Toumasi E; Georgiou D; Stylianou G; Mean R; Anastasiadou N; Athanasiou Y; Zavros M; Kyriacou K; Deltas C; Hadjianastassiou V
    Nephrol Dial Transplant; 2019 Oct; 34(10):1780-1788. PubMed ID: 30844074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant.
    Vernon KA; Gale DP; de Jorge EG; McLean AG; Galliford J; Pierides A; Maxwell PH; Taube D; Pickering MC; Cook HT
    Am J Transplant; 2011 Jan; 11(1):152-5. PubMed ID: 21114651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the alternative pathway of complement activation in glomerular diseases.
    Łukawska E; Polcyn-Adamczak M; Niemir ZI
    Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement and glomerular disease: new insights.
    Pickering M; Cook HT
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C3 glomerulopathy: what's in a name?
    D'Agati VD; Bomback AS
    Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report.
    Chen P; Zhu L; Yu F; Han SS; Meng SJ; Guo WY; Zhang H; Song Y
    Medicine (Baltimore); 2017 Jun; 96(24):e7144. PubMed ID: 28614243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry.
    Medjeral-Thomas N; Malik TH; Patel MP; Toth T; Cook HT; Tomson C; Pickering MC
    Kidney Int; 2014 Apr; 85(4):933-7. PubMed ID: 24067434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy.
    Oren R; Laufer J; Goldberg I; Kopolovic J; Waldherr R; Passwell JH
    Immunology; 1995 Dec; 86(4):575-83. PubMed ID: 8567024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulating complement in the kidney: insights from CFHR5 nephropathy.
    Gale DP; Pickering MC
    Dis Model Mech; 2011 Nov; 4(6):721-6. PubMed ID: 22065842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.